Israel Active

Israel’s D-Pharm has announced successful interim results in the Phase IIa clinical trial of its drug THR-18 taken in conjunction with tissue plasminogen activator (tPA) for the treatment of cerebral stroke. D-Pharm’s share price rose 117%, despite the trials taking place in the Ukraine.

Israeli life-science company Essence has launched Care@Home - an in-home care monitoring solution for the elderly and chronic disease sufferers. The system learns a person's everyday routine and detects any deviations, such as skipped meals, reduced activity or unusual events.

Clinical trials of Alpha 1 Antitrypsin (AAT), developed by Dr Eli Lewis of Ben Gurion University, reduced insulin dependence in Type 1 diabetes sufferers and cured several of the disease. Some physicians are now prescribing AAT as an off-label treatment ahead of FDA approval.

Israel’s Micromedic has reported positive results in its pilot study conducted in Peking Union Medical College Hospital (Union Hospital), a central hospital in Beijing, using the CellDetect product for the detection and identification of cervical cancer.

Israel’s Technion Institute and the Toronto-based University Health Network (UHN) have announced the establishment of the “Technion - UHN International Center for Cardiovascular Innovation”. New ways to treat heart disease can reduce the second leading cause of death in Israel and Canada.

Israeli-developed GPS-based CathMaps+ is the world’s first HIPAA-compliant mobile app for those with elevated risk of a cardiac incident. Android and iOS smartphone users share their medical history with cardiologists and tools include maps of the nearest catheterization labs.

Whilst at Israel’s Weizmann Institute, molecular geneticist Professor Michel Revel developed treatments for MS, ALS and diabetes. Now at 75 years of age, he works at his biotech Kadimastem developing pluripotent stem cells as a regenerative medicine solution for all three diseases.

(Thanks to Nevet www.broadview.org) Dr. Itai Amir of Israel’s Maayanei Hayeshua hospital discovered a new strain of bacteria when examining a patient’s blood culture. Eisenbergiella Tayi assists in digestion and has tremendous scientific importance, according to hospital experts.

CerOx from Israel’s Ornim is the only non-invasive device on the market monitoring blood flow to the brain in patients with severe brain trauma. The CerOx device uses ultrasound and near-infrared light to measure oxygen saturation and prevent brain damage. It has just raised $10 million.

Israel’s Brainsway has installed its Deep Brain Transcranial Magnetic Stimulation (TMS) systems at Stockholm's Karolinska University Hospital where they will be used immediately to treat patients with depression. Sweden has one of the highest rates of depression in the world.